<ul>
<li>杰龙公司：FDA 批准推动股价飙升</li>
</ul>
<p>杰龙公司（NASDAQ:GERN - 免费报告）- Wedbush 在 2023 年 8 月 6 日向投资者发布的研究报告中，发布了对杰龙 2026 年第一季度每股收益（EPS）的预期。Wedbush 分析师 R. Driscoll 预计该生物制药公司本季度每股收益为（$0.02）。杰龙当前全年的共识预期为每股收益（$0.25）。Wedbush 还对杰龙 2026 年第二季度的每股收益预期为$0.00，2026 年第三季度的每股收益预期为$0.02，2026 年第四季度的每股收益预期为$0.04，2026 财年的每股收益预期为$0.04，以及 2027 财年的每股收益预期为$0.37。</p>
<p>杰龙（NASDAQ:GERN - 获取免费报告）在 2023 年 8 月 6 日发布了季度财报。该生物制药公司报告本季度每股收益为（$0.02），超出分析师共识预期的（$0.03）$0.01。该公司本季度的收入为 4904 万美元，而分析师的预期为 4730 万美元。杰龙的股本回报率为负 30.79%，净利润率为负 53.52%。该公司的季度收入同比增长 5455.6%。在去年同期，该公司每股收益为（$0.10）。</p>
<ul>
<li>杰龙股票在伊美替斯获得 FDA 小组批准后翻倍</li>
</ul>
<p>GERN 曾是几份其他研究报告的主题。高盛集团在 2023 年 7 月 10 日发布的研究报告中对杰龙进行了覆盖，给予 “卖出” 评级，并设定目标价为$1.00。加拿大丰业银行在 2023 年 5 月 8 日的研究报告中将杰龙的评级从 “行业跑赢” 下调至 “行业表现”，并将其目标价从$4.00 下调至$1.50。一位股票研究分析师给予该股票 “卖出” 评级，三位给予 “持有” 评级，五位给予 “买入” 评级，一位给予 “强烈买入” 评级。根据 MarketBeat.com 的数据，杰龙的共识评级为 “适度买入”，共识目标价为$4.61。</p>
<p><strong>查看我们最新的杰龙股票报告</strong></p>
<h2>杰龙股票表现</h2>
<p>在周五的午盘交易中，GERN 下跌$0.02，报$1.29。该公司的交易量为 2,104,608 股，而其平均交易量为 12,713,486 股。该公司的速动比率为 6.97，流动比率为 7.87，债务与股本比率为 0.44。该公司的 50 日移动平均线为$1.39，200 日移动平均线为$1.68。该公司的市值为 8.1844 亿美元，市盈率为-9.88，贝塔值为 0.73。杰龙的 1 年最低价为$1.09，1 年最高价为$4.84。</p>
<h2>机构投资者对杰龙的看法</h2>
<p>机构投资者最近调整了对该股票的持有。Integrated Wealth Concepts LLC 在第四季度购买了杰龙的新股份，价值约$36,000。GF Fund Management CO. LTD.在第四季度购买了杰龙的新股份，价值$45,000。111 Capital 在第四季度购买了杰龙的新股份，价值$52,000。Fifth Lane Capital LP 在第四季度购买了杰龙的新股份，价值$53,000。最后，Harvest Investment Services LLC 在第四季度购买了杰龙的新股份，价值$61,000。73.71% 的股票由机构投资者持有。</p>
<h2>关于杰龙</h2>
<p>（获取免费报告）</p>
<p>杰龙公司是一家处于后期临床阶段的生物制药公司，专注于针对髓系血液恶性肿瘤的治疗药物的开发和商业化。它开发的伊美替斯是一种端粒酶抑制剂，目前处于第三阶段临床试验中，能够抑制髓系血液恶性肿瘤中恶性干细胞和祖细胞的失控增殖，用于治疗低风险或中等风险的骨髓增生异常综合症以及中等风险或高风险的骨髓纤维化。</p>
<h2>另请参阅</h2>
<ul>
<li>我们更看好的五只股票比杰龙更好</li>
<li>什么是 MACD 指标以及如何在交易中使用它</li>
<li>为什么 Axon 的 16% 飙升预示着公共安全技术的新纪元</li>
<li>高分红 REIT：它们是理想的多元化方式吗？</li>
<li>DraftKings 发布创纪录季度，瞄准盈利</li>
<li>内部人士卖出解释：它能否影响你的投资选择？</li>
<li>亚马逊在 IonQ 中获得股权投资——有任何上升潜力吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0VSTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0VSTg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在杰龙吗？</h2>
<p>在你考虑杰龙之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而杰龙并不在名单上。</p>
<p>虽然杰龙目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得买入。</p>
<p>查看这五只股票</p>

杰龙公司

<p>Wedbush 发布了对杰龙公司（NASDAQ: GERN）2026 年第一季度的收益预估，预计每股收益为（$0.02）。全年共识为每股（$0.25）。杰龙在上个季度报告的收入为 4904 万美元，超出预期。该股票获得了分析师的混合评级，综合评级为 “适度买入”，目标价格为 4.61 美元。杰龙专注于血液恶性肿瘤的治疗，其关键产品 imetelstat 正在进行第三阶段临床试验</p>

<ul>
<li>Geron Corporation: FDA Approval Fuels Stock Price Surge</li>
</ul>
<div class="lb-trans"><ul>
<li>杰龙公司：FDA 批准推动股价飙升</li>
</ul>
</div><p>Geron Corporation (NASDAQ:GERN - Free Report) - Wedbush issued their Q1 2026 earnings per share (EPS) estimates for Geron in a research note issued to investors on Wednesday, August 6th. Wedbush analyst R. Driscoll expects that the biopharmaceutical company will earn ($0.02) per share for the quarter. The consensus estimate for Geron's current full-year earnings is ($0.25) per share. Wedbush also issued estimates for Geron's Q2 2026 earnings at $0.00 EPS, Q3 2026 earnings at $0.02 EPS, Q4 2026 earnings at $0.04 EPS, FY2026 earnings at $0.04 EPS and FY2027 earnings at $0.37 EPS.</p>
<div class="lb-trans"><p>杰龙公司（NASDAQ:GERN - 免费报告）- Wedbush 在 2023 年 8 月 6 日向投资者发布的研究报告中，发布了对杰龙 2026 年第一季度每股收益（EPS）的预期。Wedbush 分析师 R. Driscoll 预计该生物制药公司本季度每股收益为（$0.02）。杰龙当前全年的共识预期为每股收益（$0.25）。Wedbush 还对杰龙 2026 年第二季度的每股收益预期为$0.00，2026 年第三季度的每股收益预期为$0.02，2026 年第四季度的每股收益预期为$0.04，2026 财年的每股收益预期为$0.04，以及 2027 财年的每股收益预期为$0.37。</p>
</div><p>Geron (NASDAQ:GERN - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.01. The business had revenue of $49.04 million during the quarter, compared to analysts' expectations of $47.30 million. Geron had a negative return on equity of 30.79% and a negative net margin of 53.52%. The business's quarterly revenue was up 5455.6% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.10) earnings per share.</p>
<div class="lb-trans"><p>杰龙（NASDAQ:GERN - 获取免费报告）在 2023 年 8 月 6 日发布了季度财报。该生物制药公司报告本季度每股收益为（$0.02），超出分析师共识预期的（$0.03）$0.01。该公司本季度的收入为 4904 万美元，而分析师的预期为 4730 万美元。杰龙的股本回报率为负 30.79%，净利润率为负 53.52%。该公司的季度收入同比增长 5455.6%。在去年同期，该公司每股收益为（$0.10）。</p>
</div><ul>
<li>Geron Stock Doubles After Imetelstat Receives FDA Panel Approval</li>
</ul>
<div class="lb-trans"><ul>
<li>杰龙股票在伊美替斯获得 FDA 小组批准后翻倍</li>
</ul>
</div><p>GERN has been the subject of several other research reports. The Goldman Sachs Group initiated coverage on Geron in a research report on Thursday, July 10th. They set a &#34;sell&#34; rating and a $1.00 target price for the company. Scotiabank cut Geron from a &#34;sector outperform&#34; rating to a &#34;sector perform&#34; rating and cut their target price for the stock from $4.00 to $1.50 in a research report on Thursday, May 8th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Geron has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $4.61.</p>
<div class="lb-trans"><p>GERN 曾是几份其他研究报告的主题。高盛集团在 2023 年 7 月 10 日发布的研究报告中对杰龙进行了覆盖，给予 “卖出” 评级，并设定目标价为$1.00。加拿大丰业银行在 2023 年 5 月 8 日的研究报告中将杰龙的评级从 “行业跑赢” 下调至 “行业表现”，并将其目标价从$4.00 下调至$1.50。一位股票研究分析师给予该股票 “卖出” 评级，三位给予 “持有” 评级，五位给予 “买入” 评级，一位给予 “强烈买入” 评级。根据 MarketBeat.com 的数据，杰龙的共识评级为 “适度买入”，共识目标价为$4.61。</p>
</div><p><strong>View Our Latest Stock Report on GERN</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的杰龙股票报告</strong></p>
</div><h2>Geron Stock Performance</h2>
<div class="lb-trans"><h2>杰龙股票表现</h2>
</div><p>GERN traded down $0.02 during midday trading on Friday, reaching $1.29. The company had a trading volume of 2,104,608 shares, compared to its average volume of 12,713,486. The company has a quick ratio of 6.97, a current ratio of 7.87 and a debt-to-equity ratio of 0.44. The business has a 50-day moving average of $1.39 and a two-hundred day moving average of $1.68. The company has a market cap of $818.44 million, a P/E ratio of -9.88 and a beta of 0.73. Geron has a 1 year low of $1.09 and a 1 year high of $4.84.</p>
<div class="lb-trans"><p>在周五的午盘交易中，GERN 下跌$0.02，报$1.29。该公司的交易量为 2,104,608 股，而其平均交易量为 12,713,486 股。该公司的速动比率为 6.97，流动比率为 7.87，债务与股本比率为 0.44。该公司的 50 日移动平均线为$1.39，200 日移动平均线为$1.68。该公司的市值为 8.1844 亿美元，市盈率为-9.88，贝塔值为 0.73。杰龙的 1 年最低价为$1.09，1 年最高价为$4.84。</p>
</div><h2>Institutional Investors Weigh In On Geron</h2>
<div class="lb-trans"><h2>机构投资者对杰龙的看法</h2>
</div><p>Institutional investors have recently modified their holdings of the stock. Integrated Wealth Concepts LLC bought a new stake in shares of Geron in the 4th quarter valued at approximately $36,000. GF Fund Management CO. LTD. purchased a new stake in Geron in the fourth quarter worth $45,000. 111 Capital bought a new stake in shares of Geron during the fourth quarter worth $52,000. Fifth Lane Capital LP bought a new stake in shares of Geron during the fourth quarter worth $53,000. Finally, Harvest Investment Services LLC bought a new stake in shares of Geron during the fourth quarter worth $61,000. 73.71% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>机构投资者最近调整了对该股票的持有。Integrated Wealth Concepts LLC 在第四季度购买了杰龙的新股份，价值约$36,000。GF Fund Management CO. LTD.在第四季度购买了杰龙的新股份，价值$45,000。111 Capital 在第四季度购买了杰龙的新股份，价值$52,000。Fifth Lane Capital LP 在第四季度购买了杰龙的新股份，价值$53,000。最后，Harvest Investment Services LLC 在第四季度购买了杰龙的新股份，价值$61,000。73.71% 的股票由机构投资者持有。</p>
</div><h2>About Geron</h2>
<div class="lb-trans"><h2>关于杰龙</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.</p>
<div class="lb-trans"><p>杰龙公司是一家处于后期临床阶段的生物制药公司，专注于针对髓系血液恶性肿瘤的治疗药物的开发和商业化。它开发的伊美替斯是一种端粒酶抑制剂，目前处于第三阶段临床试验中，能够抑制髓系血液恶性肿瘤中恶性干细胞和祖细胞的失控增殖，用于治疗低风险或中等风险的骨髓增生异常综合症以及中等风险或高风险的骨髓纤维化。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参阅</h2>
</div><ul>
<li>Five stocks we like better than Geron</li>
<li>What is the MACD Indicator and How to Use it in Your Trading</li>
<li>Why Axon's 16% Surge Signals a New Era in Public Safety Tech</li>
<li>High Dividend REITs: Are They an Ideal Way to Diversify?</li>
<li>DraftKings Posts Record Quarter, Eyes Profitability</li>
<li>Insider Selling Explained: Can it Inform Your Investing Choices?</li>
<li>Amazon Takes an Equity Stake in IonQ—Any Upside Potential?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比杰龙更好</li>
<li>什么是 MACD 指标以及如何在交易中使用它</li>
<li>为什么 Axon 的 16% 飙升预示着公共安全技术的新纪元</li>
<li>高分红 REIT：它们是理想的多元化方式吗？</li>
<li>DraftKings 发布创纪录季度，瞄准盈利</li>
<li>内部人士卖出解释：它能否影响你的投资选择？</li>
<li>亚马逊在 IonQ 中获得股权投资——有任何上升潜力吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0VSTg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=GERN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前经过 MarketBeat 编辑团队的审查。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Geron Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在杰龙吗？</h2>
</div><p>Before you consider Geron, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑杰龙之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Geron wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而杰龙并不在名单上。</p>
</div><p>While Geron currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然杰龙目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得买入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Wedbush 对杰龙公司第一季度收益的预测是什么？